Last reviewed · How we verify
Interferon-alpha2a
Interferon-alpha2a activates the innate immune system by binding to interferon-alpha receptors on immune cells and tumor cells, enhancing antiviral and anti-tumor immune responses.
Interferon-alpha2a activates the innate immune system by binding to interferon-alpha receptors on immune cells and tumor cells, enhancing antiviral and anti-tumor immune responses. Used for Metastatic melanoma, Chronic myeloid leukemia (CML), Follicular lymphoma.
At a glance
| Generic name | Interferon-alpha2a |
|---|---|
| Also known as | Roferon |
| Sponsor | Royal Marsden NHS Foundation Trust |
| Drug class | Cytokine; Interferon |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon-alpha2a is a cytokine that binds to type I interferon receptors (IFNAR1/IFNAR2) on cell surfaces, triggering JAK-STAT signaling pathways. This activation enhances natural killer cell and cytotoxic T lymphocyte activity, increases antigen presentation, and induces apoptosis in tumor cells. It also has direct antiproliferative and antiangiogenic effects on malignant cells.
Approved indications
- Metastatic melanoma
- Chronic myeloid leukemia (CML)
- Follicular lymphoma
- Hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Leukopenia
- Thrombocytopenia
- Anemia
- Depression/mood changes
- Thyroid dysfunction
- Autoimmune phenomena
Key clinical trials
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients (NA)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (PHASE1, PHASE2)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |